Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

N/ACompletedNCT05194371

Chinese Academy of Medical Sciences3,000 enrolled

Overview

In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation, economic burden, and quality of life.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Esophageal Neoplasms

Interventions

definitive radiotherapy or definitive chemoradiotherapyRADIATION

A total dose of radiation therapy should be more than 50Gy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with esophageal cancer who received definitive radiotherapy (radiotherapy dose ≥50Gy) from 2015 to 2016 2. Age ≥ 18 3. The radiation field included primary esophageal tumor with or without lymph node metastasis Exclusion Criteria: 1. Radiotherapy dose \< 50Gy 2. Palliative radiotherapy 3. The radiation field are metastatic areas, such as bone, brain, adrenal gland, isolated metastatic lymph nodes, etc

Locations (1)

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)

Beijing, China

Outcomes

Primary Outcomes

Overall survival

Time frame: 5 year

Secondary Outcomes

the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess quality of life (QOL)

The EORTC QLQ-core 30 questionnaire is composed of multi-item scales and single-item measures including 5 functional scales, 3 symptom scales, a global health status-QoL scale, and 6 single items. Each of the multi-item scales includes a different set of items - no item occurs in more than 1 scale. High scale score=higher response level; a high score for a functional scale=a healthy level of function, high score for the global health status/QoL=high quality of life but a high score for a symptom scale / item=high level of symptomatology/problems. The principle for scoring these scales: 1.) Estimate the average of the items that contribute to the scale = raw score. 2.) Linear transformation to standardize the raw score, so that scores range from 0 to 100. Results should be interpreted with caution as the numbers of patients with available data over time were limited, and because of high variances as evidenced by large standard deviations.

Time frame: 5 year

Costs of treatment

Financial burden, Whether medical insurance is affordable

Time frame: 5 year

Proportion of using chemotherapy or target therapy concurrently with radiotherapy

Medication

Time frame: 2 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.